tiprankstipranks
Nektar Therapeutics Sells Manufacturing Facility for $90M
Company Announcements

Nektar Therapeutics Sells Manufacturing Facility for $90M

Don't Miss our Black Friday Offers:

The latest update is out from Nektar Therapeutics ( (NKTR) ).

Nektar Therapeutics has entered into an agreement to sell its Huntsville, Alabama manufacturing facility to Ampersand Capital Partners for $90 million, including cash and equity. This strategic move will allow Nektar to focus on its core R&D programs in immunology while ensuring continuity in supply for existing customers. Ampersand plans to invest further in the facility, transforming it into a standalone business, highlighting its commitment to growth in the life sciences sector.

See more data about NKTR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyNektar presents preclinical data on NKTR-422 at ACR conference
TipRanks Auto-Generated NewsdeskNektar Therapeutics Reports Stable Q3 Earnings for 2024
TheFlyNektar reports Q3 EPS (18c), consensus (20c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App